Medical practices face staffing shortages and rising costs, prompting innovative strategies for health benefits to enhance ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Throughout my 25-year career in clinical oncology and translational cancer research, I have frequently encountered financial ...

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...